Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a ...

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The latest trading session saw Hims & Hers Health, Inc. (HIMS) ending at $37.04, denoting a -0.99% adjustment from its last day's close. This change lagged the S&P 500's daily gain of 0.16%. At the ...

A skincare startup got bought for $190 million—then shut down. Here's what entrepreneurs can learn from the rise and fall of ...

Health care companies slid as traders retreated from high-risk issues. Shares of obesity-drug maker Novo Nordisk and Hims & Hers Health, the compounding pharmacy seeking to compete with the ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

Discover how Meta's India, WhatsApp, and AI businesses are poised to drive growth and boost cash flows, shaping the company's ...